131 related articles for article (PubMed ID: 30010995)
1. Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing.
Cantero D; Rodríguez de Lope Á; Moreno de la Presa R; Sepúlveda JM; Borrás JM; Castresana JS; D'Haene N; García JF; Salmon I; Mollejo M; Rey JA; Hernández-Laín A; Meléndez B
J Neuropathol Exp Neurol; 2018 Aug; 77(8):710-716. PubMed ID: 30010995
[TBL] [Abstract][Full Text] [Related]
2. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.
Cantero D; Mollejo M; Sepúlveda JM; D'Haene N; Gutiérrez-Guamán MJ; Rodríguez de Lope Á; Fiaño C; Castresana JS; Lebrun L; Rey JA; Salmon I; Meléndez B; Hernández-Laín A
Neurooncol Adv; 2020; 2(1):vdz059. PubMed ID: 32642724
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.
Michaelsen SR; Urup T; Olsen LR; Broholm H; Lassen U; Poulsen HS
J Neurooncol; 2018 May; 137(3):533-542. PubMed ID: 29305787
[TBL] [Abstract][Full Text] [Related]
4. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
5. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
6. Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?
Sarmiento JM; Mukherjee D; Black KL; Fan X; Hu JL; Nuno MA; Patil CG
J Neurol Surg A Cent Eur Neurosurg; 2016 May; 77(3):195-200. PubMed ID: 26935296
[TBL] [Abstract][Full Text] [Related]
7. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.
Kraus JA; Wenghoefer M; Glesmann N; Mohr S; Beck M; Schmidt MC; Schröder R; Berweiler U; Roggendorf W; Diete S; Dietzmann K; Heuser K; Müller B; Fimmers R; von Deimling A; Schlegel U
J Neurooncol; 2001 May; 52(3):263-72. PubMed ID: 11519857
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma: pathology, molecular mechanisms and markers.
Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A
Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888
[TBL] [Abstract][Full Text] [Related]
9. GBM-associated mutations and altered protein expression are more common in young patients.
Ferguson SD; Xiu J; Weathers SP; Zhou S; Kesari S; Weiss SE; Verhaak RG; Hohl RJ; Barger GR; Reddy SK; Heimberger AB
Oncotarget; 2016 Oct; 7(43):69466-69478. PubMed ID: 27579614
[TBL] [Abstract][Full Text] [Related]
10. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
Paldor I; Drummond KJ; Kaye AH
J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
[TBL] [Abstract][Full Text] [Related]
11. Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors.
Paldor I; Pearce FC; Drummond KJ; Kaye AH
J Clin Neurosci; 2016 Dec; 34():128-132. PubMed ID: 27593971
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain.
Geisenberger C; Mock A; Warta R; Rapp C; Schwager C; Korshunov A; Nied AK; Capper D; Brors B; Jungk C; Jones D; Collins VP; Ichimura K; Bäcklund LM; Schnabel E; Mittelbron M; Lahrmann B; Zheng S; Verhaak RG; Grabe N; Pfister SM; Hartmann C; von Deimling A; Debus J; Unterberg A; Abdollahi A; Herold-Mende C
Acta Neuropathol; 2015 Sep; 130(3):419-34. PubMed ID: 25931051
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
Chaurasia A; Park SH; Seo JW; Park CK
J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
[TBL] [Abstract][Full Text] [Related]
14. Molecular characteristics and clinical features of multifocal glioblastoma.
Dono A; Wang E; Lopez-Rivera V; Ramesh AV; Tandon N; Ballester LY; Esquenazi Y
J Neurooncol; 2020 Jun; 148(2):389-397. PubMed ID: 32440969
[TBL] [Abstract][Full Text] [Related]
15. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation profiles of long- and short-term glioblastoma survivors.
Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F
Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.
Abou-El-Ardat K; Seifert M; Becker K; Eisenreich S; Lehmann M; Hackmann K; Rump A; Meijer G; Carvalho B; Temme A; Schackert G; Schröck E; Krex D; Klink B
Neuro Oncol; 2017 Apr; 19(4):546-557. PubMed ID: 28201779
[TBL] [Abstract][Full Text] [Related]
19. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
20. A simplified approach for molecular classification of glioblastomas (GBMs): experience from a tertiary care center in India.
Purkait S; Mallick S; Sharma V; Kumar A; Pathak P; Jha P; Biswas A; Julka PK; Gupta D; Suri A; Upadhyay AD; Suri V; Sharma MC; Sarkar C
Brain Tumor Pathol; 2016 Jul; 33(3):183-90. PubMed ID: 26865311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
